Close Menu
Home › Sequenom Q2 Revenues Fall 11 Percent on Lower Reimbursement Rates for NIPT

Sequenom Q2 Revenues Fall 11 Percent on Lower Reimbursement Rates for NIPT

Aug 08, 2016

This article has been updated to clarify the reasons for the year-over-year decline in diagnostic services revenue.

NEW YORK (GenomeWeb) – Sequenom's second quarter 2016 revenues fell 11 percent compared to the second quarter of 2015, the firm reported in a filing with the US Securities Exchange Commission.

The molecular diagnostics company reported $29.3 million in Q2 2016 revenues, down from $32.8 million in Q2 2015, missing analysts' average estimate of $30.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

What's Popular?

In Sequencing

  1. Liquid Biopsy Assay From MSKCC Approved by New York State

  2. AmoyDx, Premia Partner With Loxo on Genetic Testing for Cancer Therapy

  3. AMP and CAP Comment on Palmetto Proposed Guidelines for NGS Testing of Myeloid Disorders

  4. NIH Newborn Sequencing Projects' Lessons, Next Steps Highlighted at Meeting

    Premium

  5. Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.